Strategies for development of dengue virus inhibitors

Antiviral Research

Volumn 85, Issue 3, 2010, Pages 450-462

  Noble, Christian G ^a   Chen, Yen Liang ^a   Dong, Hongping ^a   Gu, Feng ^a   Lim, Siew Pheng ^a   Schul, Wouter ^a   Wang, Qing Yin ^a   Shi, Pei Yong ^a  

^a NOVARTIS INSTITUTE FOR TROPICAL DISEASES   (Singapore)

Author keywords

Antiviral; Cell based assay; Dengue virus; Drug discovery; Enzyme assay; Flavivirus; High throughput screening

Indexed keywords

1 DEOXYNOJIRIMYCIN; ADEFOVIR DIPIVOXIL; ADENOSINE DERIVATIVE; ALPHA GLUCOSIDASE; AMPRENAVIR; ANTIVIRUS AGENT; APROTININ; CAPSID PROTEIN; CASTANOSPERMINE; CELL SURFACE RECEPTOR; ENFUVIRTIDE; FC RECEPTOR; INTERLEUKIN 8 ANTIBODY; MARAVIROC; NITD 008; NONSTRUCTURAL PROTEIN 2; NONSTRUCTURAL PROTEIN 3; NUCLEOSIDE ANALOG; PALIVIZUMAB; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; RNA DIRECTED RNA POLYMERASE; RNA HELICASE; RNA METHYLTRANSFERASE; SERINE PROTEINASE INHIBITOR; TENOFOVIR DISOPROXIL; TUMOR NECROSIS FACTOR ANTIBODY; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIRUS ENVELOPE PROTEIN; VIRUS PROTEIN;

ANTIVIRAL ACTIVITY; DENGUE; DENGUE VIRUS; DRUG BINDING SITE; DRUG DESIGN; DRUG IDENTIFICATION; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG RESEARCH; DRUG SCREENING; DRUG TARGETING; HEPATITIS B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MITOCHONDRIAL TOXICITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; RNA METHYLATION; STRUCTURE ACTIVITY RELATION; VIRUS INFECTION; VIRUS REPLICATION;

ANTIVIRAL AGENTS; DENGUE VIRUS; DRUG DISCOVERY; HUMANS;

DENGUE VIRUS; FLAVIVIRUS;

EID: 76949091459     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2009.12.011     Document Type: Review

References (154)

1. Ackermann M., and Padmanabhan R. De novo synthesis of RNA by the dengue virus RNA-dependent RNA polymerase exhibits temperature dependence at the initiation but not elongation phase. J. Biol. Chem. 276 43 (2001) 39926-39937
2. Alen M.M., Kaptein S.J., De Burghgraeve T., Balzarini J., Neyts J., and Schols D. Antiviral activity of carbohydrate-binding agents and the role of DC-SIGN in dengue virus infection. Virology 387 1 (2009) 67-75
3. Aleshin A., Shiryaev S., Strongin A., and Liddington R. Structural evidence for regulation and specificity of flaviviral proteases and evolution of the Flaviviridae fold. Protein Sci. 16 5 (2007) 795-806
4. Antonysamy S.S., Aubol B., Blaney J., Browner M.F., Giannetti A.M., Harris S.F., Hebert N., Hendle J., Hopkins S., Jefferson E., Kissinger C., Leveque V., Marciano D., McGee E., Najera I., Nolan B., Tomimoto M., Torres E., and Wright T. Fragment-based discovery of hepatitis C virus NS5b RNA polymerase inhibitors. Bioorg. Med. Chem. Lett. 18 9 (2008) 2990-2995
5. Atrasheuskaya A., Petzelbauer P., Fredeking T.M., and Ignatyev G. Anti-TNF antibody treatment reduces mortality in experimental dengue virus infection. FEMS Immunol. Med. Microbiol. 35 1 (2003) 33-42
6. Barbas III C.F., Heine A., Zhong G., Hoffmann T., Gramatikova S., Bjornestedt R., List B., Anderson J., Stura E.A., Wilson I.A., and Lerner R.A. Immune versus natural selection: antibody aldolases with enzymic rates but broader scope. Science 278 5346 (1997) 2085-2092
7. Bazan J.F., and Fletterick R.J. Detection of a trypsin-like serine protease domain in flaviviruses and pestiviruses. Virology 171 2 (1989) 637-639
8. Beaulieu P.L., Gillard J., Bykowski D., Brochu C., Dansereau N., Duceppe J.S., Hache B., Jakalian A., Lagace L., LaPlante S., McKercher G., Moreau E., Perreault S., Stammers T., Thauvette L., Warrington J., and Kukolj G. Improved replicon cellular activity of non-nucleoside allosteric inhibitors of HCV NS5B polymerase: from benzimidazole to indole scaffolds. Bioorg. Med. Chem. Lett. 16 19 (2006) 4987-4993
9. Bente D.A., Melkus M.W., Garcia J.V., and Rico-Hesse R. Dengue fever in humanized NOD/SCID mice. J. Virol. 79 21 (2005) 13797-13799
10. Berkowitz F.E., and Levin M.J. Use of an enzyme-linked immunosorbent assay performed directly on fixed infected cell monolayers for evaluating drugs against varicella-zoster virus. Antimicrob. Agents Chemother. 28 2 (1985) 207-210
11. Betz U.A., Fischer R., Kleymann G., Hendrix M., and Rubsamen-Waigmann H. Potent in vivo antiviral activity of the herpes simplex virus primase-helicase inhibitor BAY 57-1293. Antimicrob. Agents Chemother. 46 6 (2002) 1766-1772
12. Biswas S., Jennens L., and Field H.J. The helicase primase inhibitor, BAY 57-1293 shows potent therapeutic antiviral activity superior to famciclovir in BALB/c mice infected with herpes simplex virus type 1. Antiviral Res. 75 1 (2007) 30-35
13. Boguszewska-Chachulska A.M., Krawczyk M., Stankiewicz A., Gozdek A., Haenni A.L., and Strokovskaya L. Direct fluorometric measurement of hepatitis C virus helicase activity. FEBS Lett. 567 2-3 (2004) 253-258
14. Carroll S.S., Ludmerer S., Handt L., Koeplinger K., Zhang N.R., Graham D., Davies M.E., MacCoss M., Hazuda D., and Olsen D.B. Robust antiviral efficacy upon administration of a nucleoside analog to hepatitis C virus-infected chimpanzees. Antimicrob. Agents Chemother. 53 3 (2009) 926-934
15. Carroll S.S., and Olsen D.B. Nucleoside analog inhibitors of hepatitis C virus replication. Infect. Disord. Drug Targets 6 1 (2006) 17-29
16. Chambers T.J., Grakoui A., and Rice C.M. Processing of the yellow fever virus nonstructural polyprotein: a catalytically active NS3 proteinase domain and NS2B are required for cleavages at dibasic sites. J. Virol. 65 11 (1991) 6042-6050
17. Chambers T.J., Weir R.C., Grakoui A., McCourt D.W., Bazan J.F., Fletterick R.J., and Rice C.M. Evidence that the N-terminal domain of nonstructural protein NS3 from yellow fever virus is a serine protease responsible for site-specific cleavages in the viral polyprotein. Proc. Nat. Acad. Sci. U.S.A. 87 22 (1990) 8898-8902
18. Chen S.T., Lin Y.L., Huang M.T., Wu M.F., Cheng S.C., Lei H.Y., Lee C.K., Chiou T.W., Wong C.H., and Hsieh S.L. CLEC5A is critical for dengue-virus-induced lethal disease. Nature 453 7195 (2008) 672-676
19. Chu J., Rajamanonmani R., Li J., Bhuvanakantham R., Lescar J., and Ng M. Inhibition of West Nile virus entry by using a recombinant domain III from the envelope glycoprotein. J. Gen. Virol. 86 Pt 2 (2005) 405-412
20. Chu J.J., and Yang P.L. c-Src protein kinase inhibitors block assembly and maturation of dengue virus. Proc. Natl. Acad. Sci. U.S.A. 104 9 (2007) 3520-3525
21. Cleaves G.R., and Dubin D.T. Methylation status of intracellular Dengue type 2 40S RNA. Virology 96 (1979) 159-165
22. Cordin O., Banroques J., Tanner N.K., and Linder P. The DEAD-box protein family of RNA helicases. Gene 367 (2006) 17-37
23. Cote H.C., Brumme Z.L., Craib K.J., Alexander C.S., Wynhoven B., Ting L., Wong H., Harris M., Harrigan P.R., O'Shaughnessy M.V., and Montaner J.S. Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients. N. Engl. J. Med. 346 11 (2002) 811-820
24. Courageot M.P., Frenkiel M.P., Dos Santos C.D., Deubel V., and Despres P. Alpha-glucosidase inhibitors reduce dengue virus production by affecting the initial steps of virion morphogenesis in the endoplasmic reticulum. J. Virol. 74 1 (2000) 564-572
25. Crill W.D., and Roehrig J.T. Monoclonal antibodies that bind to domain III of dengue virus E glycoprotein are the most efficient blockers of virus adsorption to Vero cells. J. Virol. 75 16 (2001) 7769-7773
26. Dong H., Ray D., Ren S., Zhang B., Puig-Basagoiti F., Takagi Y., Ho C., Li H., and Shi P. Distinct RNA elements confer specificity to flavivirus RNA cap methylation events. J. Virol. 81 9 (2007) 4412-4421
27. Dong H., Zhang B., and Shi P.Y. Flavivirus methyltransferase: a novel antiviral target. Antiviral Res. 80 1 (2008) 1-10
28. Earnshaw D.L., Moore K.J., Greenwood C.J., Djaballah H., Jurewicz A.J., Murray K.J., and Pope A.J. Time-resolved fluorescence energy transfer DNA helicase assays for high throughput screening. J. Biomol. Screen. 4 5 (1999) 239-248
29. Egloff M.P., Benarroch D., Selisko B., Romette J.L., and Canard B. An RNA cap (nucleoside-2′-O-)-methyltransferase in the flavivirus RNA polymerase NS5: crystal structure and functional characterization. EMBO J. 21 11 (2002) 2757-2768
30. Egloff M.P., Decroly E., Malet H., Selisko B., Benarroch D., Ferron F., and Canard B. Structural and functional analysis of methylation and 5′-RNA sequence requirements of short capped RNAs by the methyltransferase domain of dengue virus NS5. J. Mol. Biol. 372 3 (2007) 723-736
31. Ekonomiuk D., Su X.C., Ozawa K., Bodenreider C., Lim S.P., Yin Z., Keller T.H., Beer D., Patel V., Otting G., Caflisch A., and Huang D. Discovery of a non-peptidic inhibitor of west nile virus NS3 protease by high-throughput docking. PLoS Negl. Trop. Dis. 3 1 (2009) e356
32. Elshuber S., Allison S.L., Heinz F.X., and Mandl C.W. Cleavage of protein prM is necessary for infection of BHK-21 cells by tick-borne encephalitis virus. J. Gen. Virol. 84 Pt 1 (2003) 183-191
33. Erbel P., Schiering N., D'Arcy A., Renatus M., Kroemer M., Lim S., Yin Z., Keller T., Vasudevan S., and Hommel U. Structural basis for the activation of flaviviral NS3 proteases from dengue and West Nile virus. Nat. Struct. Mol. Biol. 13 4 (2006) 372-373
34. Falgout B., Miller R.H., and Lai C.J. Deletion analysis of dengue virus type 4 nonstructural protein NS2B: identification of a domain required for NS2B-NS3 protease activity. J. Virol. 67 4 (1993) 2034-2042
35. Fenouillet E., and Gluckman J.C. Effect of a glucosidase inhibitor on the bioactivity and immunoreactivity of human immunodeficiency virus type 1 envelope glycoprotein. J. Gen. Virol. 72 Pt 8 (1991) 1919-1926
36. Furuichi Y., and Shatkin A.J. Viral and cellular mRNA capping: past and prospects. Adv. Virus Res. 55 (2000) 135-184
37. Goncalvez A.P., Engle R.E., St Claire M., Purcell R.H., and Lai C.J. Monoclonal antibody-mediated enhancement of dengue virus infection in vitro and in vivo and strategies for prevention. Proc. Natl. Acad. Sci. U.S.A. 104 22 (2007) 9422-9427
38. Gouvea I.E., Izidoro M.A., Judice W.A., Cezari M.H., Caliendo G., Santagada V., dos Santos C.N., Queiroz M.H., Juliano M.A., Young P.R., Fairlie D.P., and Juliano L. Substrate specificity of recombinant dengue 2 virus NS2B-NS3 protease: influence of natural and unnatural basic amino acids on hydrolysis of synthetic fluorescent substrates. Arch. Biochem. Biophys. 457 2 (2007) 187-196
39. Green N., Ott R., Isaacs R., and Fang H. Cell-based assays to identify inhibitors of viral disease. Expert Opin. Drug Discov. 3 (2008) 671-676
40. Gromowski G.D., Barrett N.D., and Barrett A.D. Characterization of dengue virus complex-specific neutralizing epitopes on envelope protein domain III of dengue 2 virus. J. Virol. 82 17 (2008) 8828-8837
41. Gu B., Mason P., Wang L., Norton P., Bourne N., Moriarty R., Mehta A., Despande M., Shah R., and Block T. Antiviral profiles of novel iminocyclitol compounds against bovine viral diarrhea virus, West Nile virus, dengue virus and hepatitis B virus. Antivir. Chem. Chemother. 18 1 (2007) 49-59
42. Gubler D., Kuno G., and Markoff L. Flaviviruses. In: Knipe D.M., and Howley P.M. (Eds). Fields Virology. 5th ed. vol. 1 (2007), Lippincott William & Wilkins, Philadelphia, PA 1153-1253
43. Gubler D.J., Suharyono W., Lubis I., Eram S., and Gunarso S. Epidemic dengue 3 in central Java, associated with low viremia in man. Am. J. Trop. Med. Hyg. 30 5 (1981) 1094-1099
44. Guo J., Hayashi J., and Seeger C. West nile virus inhibits the signal transduction pathway of alpha interferon. J. Virol. 79 3 (2005) 1343-1350
45. Halstead S.B. Neutralization and antibody-dependent enhancement of dengue viruses. Adv. Virus Res. 60 (2003) 421-467
46. Han H., de Vrueh R.L., Rhie J.K., Covitz K.M., Smith P.L., Lee C.P., Oh D.M., Sadee W., and Amidon G.L. 5′-Amino acid esters of antiviral nucleosides, acyclovir, and AZT are absorbed by the intestinal PEPT1 peptide transporter. Pharm. Res. 15 8 (1998) 1154-1159
47. Harrison S.C. Mechanism of membrane fusion by viral envelope proteins. Adv. Virus Res. 64 (2005) 231-261
48. Hesterkamp T., and Whittaker M. Fragment-based activity space: smaller is better. Curr. Opin. Chem. Biol. 12 3 (2008) 260-268
49. Hezareh M., Hessell A.J., Jensen R.C., van de Winkel J.G., and Parren P.W. Effector function activities of a panel of mutants of a broadly neutralizing antibody against human immunodeficiency virus type 1. J. Virol. 75 24 (2001) 12161-12168
50. Hirsch A.J., Medigeshi G.R., Meyers H.L., DeFilippis V., Fruh K., Briese T., Lipkin W.I., and Nelson J.A. The Src family kinase c-Yes is required for maturation of West Nile virus particles. J. Virol. 79 18 (2005) 11943-11951
51. Hrobowski Y., Garry R., and Michael S. Peptide inhibitors of dengue virus and West Nile virus infectivity. Virol. J. 2 (2005) 49
52. Iempridee T., Thongphung R., Angsuthanasombat C., and Katzenmeier G. A comparative biochemical analysis of the NS2B(H)-NS3pro protease complex from four dengue virus serotypes. Biochim. Biophys. Acta 1780 7-8 (2008) 989-994
53. Jhoti H., Cleasby A., Verdonk M., and Williams G. Fragment-based screening using X-ray crystallography and NMR spectroscopy. Curr. Opin. Chem. Biol. 11 5 (2007) 485-493
54. Jindadamrongwech S., Thepparit C., and Smith D.R. Identification of GRP 78 (BiP) as a liver cell expressed receptor element for dengue virus serotype 2. Arch. Virol. 149 5 (2004) 915-927
55. Kandil S., Biondaro S., Vlachakis D., Cummins A.C., Coluccia A., Berry C., Leyssen P., Neyts J., and Brancale A. Discovery of a novel HCV helicase inhibitor by a de novo drug design approach. Bioorg. Med. Chem. Lett. 19 11 (2009) 2935-2937
56. Khromykh A.A., Varnavski A.N., and Westaway E.G. Encapsidation of the flavivirus Kunjin replicon RNA by using a complementation system providing Kunjin virus structural proteins in trans. J. Virol. 72 (1998) 5967-5977
57. Kroschewski H., Lim S.P., Butcher R.E., Yap T.L., Lescar J., Wright P.J., Vasudevan S.G., and Davidson A.D. Mutagenesis of the dengue virus type 2 NS5 methyltransferase domain. J. Biol. Chem. 283 28 (2008) 19410-19421
58. Kummerer B.M., and Rice C.M. Mutations in the yellow fever virus nonstructural protein NS2A selectively block production of infectious particles. J. Virol. 76 10 (2002) 4773-4784
59. Kuritzkes D.R. HIV-1 entry inhibitors: an overview. Curr. Opin. HIV AIDS 4 2 (2009) 82-87
60. Kyono K., Miyashiro M., and Taguchi I. Detection of hepatitis C virus helicase activity using the scintillation proximity assay system. Anal. Biochem. 257 2 (1998) 120-126
61. Le Pogam S., Seshaadri A., Kosaka A., Chiu S., Kang H., Hu S., Rajyaguru S., Symons J., Cammack N., and Najera I. Existence of hepatitis C virus NS5B variants naturally resistant to non-nucleoside, but not to nucleoside, polymerase inhibitors among untreated patients. J. Antimicrob. Chemother. 61 6 (2008) 1205-1216
62. Leary J.J., Wittrock R., Sarisky R.T., Weinberg A., and Levin M.J. Susceptibilities of herpes simplex viruses to penciclovir and acyclovir in eight cell lines. Antimicrob. Agents Chemother. 46 3 (2002) 762-768
63. Lee C.J., Lin H.R., Liao C.L., and Lin Y.L. Cholesterol effectively blocks entry of flavivirus. J. Virol. 82 13 (2008) 6470-6480
64. Leung D., Schroder K., White H., Fang N.-X., Stoermer M., Abbenante G., Martin J., PR Y., and Fairlie D. Activity of recombinant dengue 2 virus NS3 protease in the presence of a truncated NS2B co-factor, small peptide substrates, and inhibitors. J. Biol. Chem. 276 (2001) 45762-45771
65. Li J., Lim S.P., Beer D., Patel V., Wen D., Tumanut C., Tully D.C., Williams J.A., Jiricek J., Priestle J.P., Harris J.L., and Vasudevan S.G. Functional profiling of recombinant NS3 proteases from all four serotypes of dengue virus using tetrapeptide and octapeptide substrate libraries. J. Biol. Chem. 280 31 (2005) 28766-28774
66. Liao M., and Kielian M. Domain III from class II fusion proteins functions as a dominant-negative inhibitor of virus membrane fusion. J. Cell Biol. 171 1 (2005) 111-120
67. Libraty D.H., Young P.R., Pickering D., Endy T.P., Kalayanarooj S., Green S., Vaughn D.W., Nisalak A., Ennis F.A., and Rothman A.L. High circulating levels of the dengue virus nonstructural protein NS1 early in dengue illness correlate with the development of dengue hemorrhagic fever. J. Infect. Dis. 186 8 (2002) 1165-1168
68. Lindenbach B., and Rice C. Trans-complementation of yellow fever virus NS1 reveals a role in early RNA replication. J. Virol. 71 (1997) 9608-9617
69. Lisova O., Hardy F., Petit V., and Bedouelle H. Mapping to completeness and transplantation of a group-specific, discontinuous, neutralizing epitope in the envelope protein of dengue virus. J. Gen. Virol. 88 Pt 9 (2007) 2387-2397
70. Liu W., Wang X., Mokhonov V., Shi P., Randall R., and Khromykh A. Inhibition of interferon signaling by the New York 99 strain and Kunjin subtype of West Nile virus involves blockage of STAT1 and STAT2 activation by nonstructural proteins. J. Virol. 79 3 (2005) 1934-1942
71. Liu W.J., Chen H.B., and Khromykh A.A. Molecular and functional analyses of Kunjin virus infectious cDNA clones demonstrate the essential roles for NS2A in virus assembly and for a nonconservative residue in NS3 in RNA replication. J. Virol. 77 14 (2003) 7804-7813
72. Lok S.M., Kostyuchenko V., Nybakken G.E., Holdaway H.A., Battisti A.J., Sukupolvi-Petty S., Sedlak D., Fremont D.H., Chipman P.R., Roehrig J.T., Diamond M.S., Kuhn R.J., and Rossmann M.G. Binding of a neutralizing antibody to dengue virus alters the arrangement of surface glycoproteins. Nat. Struct. Mol. Biol. 15 3 (2008) 312-317
73. Lubeck M.D., Schulman J.L., and Palese P. Antigenic variants of influenza viruses: marked differences in the frequencies of variants selected with different monoclonal antibodies. Virology 102 2 (1980) 458-462
74. Luo D., Xu T., Hunke C., Gruber G., Vasudevan S., and Lescar J. Crystal structure of the NS3 protease-helicase from Dengue virus. J. Virol. (2007) (Epub ahead of print)
75. Luo D., Xu T., Watson R.P., Scherer-Becker D., Sampath A., Jahnke W., Yeong S.S., Wang C.H., Lim S.P., Strongin A., Vasudevan S.G., and Lescar J. Insights into RNA unwinding and ATP hydrolysis by the flavivirus NS3 protein. EMBO J. 27 23 (2008) 3209-3219
76. Luplertlop N., Misse D., Bray D., Deleuze V., Gonzalez J.P., Leardkamolkarn V., Yssel H., and Veas F. Dengue-virus-infected dendritic cells trigger vascular leakage through metalloproteinase overproduction. EMBO Rep. 7 11 (2006) 1176-1181
77. Ma L., Jones C.T., Groesch T.D., Kuhn R.J., and Post C.B. Solution structure of dengue virus capsid protein reveals another fold. Proc. Natl. Acad. Sci. U.S.A. 101 10 (2004) 3414-3419
78. Maga G., Gemma S., Fattorusso C., Locatelli G.A., Butini S., Persico M., Kukreja G., Romano M.P., Chiasserini L., Savini L., Novellino E., Nacci V., Spadari S., and Campiani G. Specific targeting of hepatitis C virus NS3 RNA helicase. Discovery of the potent and selective competitive nucleotide-mimicking inhibitor QU663. Biochemistry 44 28 (2005) 9637-9644
79. Malet H., Egloff M., Selisko B., Butcher R., Wright P., Roberts M., Gruez A., Sulzenbacher G., Vonrhein C., Bricogne G., Mackenzie J., Khromykh A., and Davidson A.B. Crystal structure of the RNA polymerase domain of the West Nile virus non-structural protein 5. J. Biol. Chem. 282 14 (2007) 10678-10689
80. Malet H., Masse N., Selisko B., Romette J.L., Alvarez K., Guillemot J.C., Tolou H., Yap T.L., Vasudevan S., Lescar J., and Canard B. The flavivirus polymerase as a target for drug discovery. Antiviral Res. 80 1 (2008) 23-35
81. Mancini E., Assenberg R., Verma A., Walter T., Tuma R., Grimes J., Owens R., and Stuart D. Structure of the Murray Valley encephalitis virus RNA helicase at 1.9 Angstrom resolution. Protein Sci. 16 10 (2007) 2294-2300
82. Marcon L., Kozak D., Battersby B.J., Chappell K.J., Fairlie D.P., Young P., and Trau M. A dual-purpose synthetic colloidal platform for protease mapping: substrate profiling for Dengue and West Nile virus proteases. Anal. Biochem. 376 1 (2008) 151-153
83. Markland W., McQuaid T.J., Jain J., and Kwong A.D. Broad-spectrum antiviral activity of the IMP dehydrogenase inhibitor VX-497: a comparison with ribavirin and demonstration of antiviral additivity with alpha interferon. Antimicrob. Agent. Chemother. 44 4 (2000) 859-866
84. Martins S., Ramos M.J., and Fernandes P.A. The current status of the NNRTI family of antiretrovirals used in the HAART regime against HIV infection. Curr. Med. Chem. 15 11 (2008) 1083-1095
85. McCown M., Diamond M.S., and Pekosz A. The utility of siRNA transcripts produced by RNA polymerase i in down regulating viral gene expression and replication of negative- and positive-strand RNA viruses. Virology 313 2 (2003) 514-524
86. Menéndez-Arias, L., 2010. Molecular basis of human immunodeficiency virus drug resistance: an update. Antiviral Res., doi:10.1016/j.antiviral.2009.07.006.
87. Migliaccio G., Tomassini J.E., Carroll S.S., Tomei L., Altamura S., Bhat B., Bartholomew L., Bosserman M.R., Ceccacci A., Colwell L.F., Cortese R., De Francesco R., Eldrup A.B., Getty K.L., Hou X.S., LaFemina R.L., Ludmerer S.W., MacCoss M., McMasters D.R., Stahlhut M.W., Olsen D.B., Hazuda D.J., and Flores O.A. Characterization of resistance to non-obligate chain-terminating ribonucleoside analogs that inhibit hepatitis C virus replication in vitro. J. Biol. Chem. 278 49 (2003) 49164-49170
88. Miller J.L., deWet B.J., Martinez-Pomares L., Radcliffe C.M., Dwek R.A., Rudd P.M., and Gordon S. The mannose receptor mediates dengue virus infection of macrophages. PLoS Pathog. 4 2 (2008) e17
89. Miller S., Kastner S., Krijnse-Locker J., Buhler S., and Bartenschlager R. The non-structural protein 4A of dengue virus is an integral membrane protein inducing membrane alterations in a 2K-regulated manner. J. Biol. Chem. 282 12 (2007) 8873-8882
90. Miller S., Sparacio S., and Bartenschlager R. Subcellular localization and membrane topology of the dengue virus type 2 non-structural protein 4B. J. Biol. Chem. 281 13 (2006) 8854-8863
91. Modis Y., Ogata S., Clements D., and Harrison S.C. A ligand-binding pocket in the dengue virus envelope glycoprotein. Proc. Natl. Acad. Sci. U.S.A. 100 12 (2003) 6986-6991
92. Modis Y., Ogata S., Clements D., and Harrison S.C. Structure of the dengue virus envelope protein after membrane fusion. Nature 427 6972 (2004) 313-319
93. Mooij W.T., Hartshorn M.J., Tickle I.J., Sharff A.J., Verdonk M.L., and Jhoti H. Automated protein-ligand crystallography for structure-based drug design. ChemMedChem 1 8 (2006) 827-838
94. Mota J., and Rico-Hesse R. Humanized mice show clinical signs of dengue fever according to infecting virus genotype. J. Virol. 83 17 (2009) 8638-8645
95. Moyle G. Toxicity of antiretroviral nucleoside and nucleotide analogues: is mitochondrial toxicity the only mechanism?. Drug Saf. 23 6 (2000) 467-481
96. Mueller N.H., Pattabiraman N., Ansarah-Sobrinho C., Viswanathan P., Pierson T.C., and Padmanabhan R. Identification and biochemical characterization of small-molecule inhibitors of west nile virus serine protease by a high-throughput screen. Antimicrob. Agents Chemother. 52 9 (2008) 3385-3393
97. Mueller N.H., Yon C., Ganesh V.K., and Padmanabhan R. Characterization of the West Nile virus protease substrate specificity and inhibitors. Int. J. Biochem. Cell Biol. 39 3 (2007) 606-614
98. Munoz-Jordan J.L., Laurent-Rolle M., Ashour J., Martinez-Sobrido L., Ashok M., Lipkin W.I., and Garcia-Sastre A. Inhibition of alpha/beta interferon signaling by the NS4B protein of flaviviruses. J. Virol. 79 13 (2005) 8004-8013
99. Munoz-Jordan J.L., Sanchez-Burgos G.G., Laurent-Rolle M., and Garcia-Sastre A. Inhibition of interferon signaling by dengue virus. Proc. Natl. Acad. Sci. U.S.A. 100 24 (2003) 14333-14338
100. Navarro-Sanchez E., Altmeyer R., Amara A., Schwartz O., Fieschi F., Virelizier J.L., Arenzana-Seisdedos F., and Despres P. Dendritic-cell-specific ICAM3-grabbing non-integrin is essential for the productive infection of human dendritic cells by mosquito-cell-derived dengue viruses. EMBO Rep. 4 7 (2003) 723-728
101. Ng C.Y., Gu F., Phong W.Y., Chen Y.L., Lim S.P., Davidson A., and Vasudevan S.G. Construction and characterization of a stable subgenomic dengue virus type 2 replicon system for antiviral compound and siRNA testing. Antiviral Res. 76 3 (2007) 222-231
102. Niyomrattanakit P., Yahorava S., Mutule I., Mutulis F., Petrovska R., Prusis P., Katzenmeier G., and Wikberg J.E. Probing the substrate specificity of the dengue virus type 2 NS3 serine protease by using internally quenched fluorescent peptides. Biochem. J. 397 1 (2006) 203-211
103. Oliphant T., Engle M., Nybakken G., Doane C., Johnson S., Huang L., Gorlatov S., Mehlhop E., Marri A., Chung K., Ebel G., Kramer L., Fremont D., and Diamond M. Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus. Nat. Med. 11 5 (2005) 522-530
104. Pang X., Zhang M., and Dayton A.I. Development of Dengue virus type 2 replicons capable of prolonged expression in host cells. BMC Microbiol. 1 (2001) 18
105. Pastor-Anglada M., Cano-Soldado P., Molina-Arcas M., Lostao M.P., Larrayoz I., Martinez-Picado J., and Casado F.J. Cell entry and export of nucleoside analogues. Virus Res. 107 2 (2005) 151-164
106. Pauwels F., Mostmans W., Quirynen L.M., van der Helm L., Boutton C.W., Rueff A.S., Cleiren E., Raboisson P., Surleraux D., Nyanguile O., and Simmen K.A. Binding-site identification and genotypic profiling of hepatitis C virus polymerase inhibitors. J. Virol. 81 13 (2007) 6909-6919
107. Pellerin C., Lefebvre S., Little M.J., McKercher G., Lamarre D., and Kukolj G. Internal initiation sites of de novo RNA synthesis within the hepatitis C virus polypyrimidine tract. Biochem. Biophys. Res. Commun. 295 3 (2002) 682-688
108. Perera R., Khaliq M., and Kuhn R.J. Closing the door on flaviviruses: entry as a target for antiviral drug design. Antiviral Res. 80 1 (2008) 11-22
109. Perrone P., Daverio F., Valente R., Rajyaguru S., Martin J.A., Leveque V., Le Pogam S., Najera I., Klumpp K., Smith D.B., and McGuigan C. First example of phosphoramidate approach applied to a 4′-substituted purine nucleoside (4′-azidoadenosine): conversion of an inactive nucleoside to a submicromolar compound versus hepatitis C virus. J. Med. Chem. 50 22 (2007) 5463-5470
110. Perrone P., Luoni G.M., Kelleher M.R., Daverio F., Angell A., Mulready S., Congiatu C., Rajyaguru S., Martin J.A., Leveque V., Le Pogam S., Najera I., Klumpp K., Smith D.B., and McGuigan C. Application of the phosphoramidate ProTide approach to 4′-azidouridine confers sub-micromolar potency versus hepatitis C virus on an inactive nucleoside. J. Med. Chem. 50 8 (2007) 1840-1849
111. Poh, M.K., Yip, A., Zhang, S., Priestle, J.P., Ma, N.L., Smit, J.M., Wilschut, J., Shi, P.-Y., Wenk, M.R., Schul, W., 2009. A small molecule fusion inhibitor of dengue virus. Antiviral Res.
112. Preugschat F., Yao C.W., and Strauss J.H. In vitro processing of dengue virus type 2 nonstructural proteins NS2A, NS2B, and NS3. J. Virol. 64 9 (1990) 4364-4374
113. Prusis P., Lapins M., Yahorava S., Petrovska R., Niyomrattanakit P., Katzenmeier G., and Wikberg J.E. Proteochemometrics analysis of substrate interactions with dengue virus NS3 proteases. Bioorg. Med. Chem. 16 20 (2008) 9369-9377
114. Puig-Basagoiti F., Tilgner M., Forshey B.M., Philpott S.M., Espina N.G., Wentworth D.E., Goebel S.J., Masters P.S., Falgout B., Ren P., Ferguson D.M., and Shi P.-Y. High-throughput assays using luciferase-expressing replicon, virus-like particle, and full-length virus for West Nile virus drug discovery. Antimicrob. Agent. Chemother. 49 12 (2005) 4980-4988
115. Puig-Basagoiti F., Tilgner M., Forshey B., Philpott S., Espina N., Wentworth D.E., Goebel S., Masters P.S., Falgout B., Ren P., Ferguson, and Shi P.Y. Triaryl pyrazoline compound inhibits flavivirus RNA replication. Antimicrob. Agents Chemother. 50 4 (2006) 1320-1329
116. Pyle A.M. Translocation and unwinding mechanisms of RNA and DNA helicases. Annu. Rev. Biophys. 37 (2008) 317-336
117. Ray D., Shah A., Tilgner M., Guo Y., Zhao Y., Dong H., Deas T., Zhou Y., Li H., and Shi P. West nile virus 5′-cap structure is formed by sequential guanine N-7 and ribose 2′-O methylations by nonstructural protein 5. J. Virol. 80 17 (2006) 8362-8370
118. Rey F.A., Heinz F.X., Mandl C., Kunz C., and Harrison S.C. The envelope glycoprotein from tick-borne encephalitis virus at 2 A resolution. Nature 375 6529 (1995) 291-298
119. Rothwell C., Lebreton A., Young Ng C., Lim J.Y., Liu W., Vasudevan S., Labow M., Gu F., and Gaither L.A. Cholesterol biosynthesis modulation regulates dengue viral replication. Virology 389 1-2 (2009) 8-19
120. Shiryaev S., Ratnikov B., Chekanov A., Sikora S., Rozanov D., Godzik A., Wang J., Smith J., Huang Z., Lindberg I., Samuel M., Diamond M., and Strongin A. Cleavage targets and the d-arginine-based inhibitors of the West Nile virus NS3 processing proteinase. Biochem. J. 393 (2006) 503-511
121. Shiryaev S.A., Chernov A.V., Aleshin A.E., Shiryaeva T.N., and Strongin A.Y. NS4A regulates the ATPase activity of the NS3 helicase: a novel cofactor role of the non-structural protein NS4A from West Nile virus. J. Gen. Virol. 90 Pt 9 (2009) 2081-2085
122. Shresta S., Sharar K.L., Prigozhin D.M., Beatty P.R., and Harris E. Murine model for dengue virus-induced lethal disease with increased vascular permeability. J. Virol. 80 20 (2006) 10208-10217
123. Sivaraja M., Giordano H., and Peterson M.G. High-throughput screening assay for helicase enzymes. Anal. Biochem. 265 1 (1998) 22-27
124. Soriano V., Madejon A., Vispo E., Labarga P., Garcia-Samaniego J., Martin-Carbonero L., Sheldon J., Bottecchia M., Tuma P., and Barreiro P. Emerging drugs for hepatitis C. Expert Opin. Emerg. Drugs 13 (2008) 1-19
125. Souza D.G., Fagundes C.T., Sousa L.P., Amaral F.A., Souza R.S., Souza A.L., Kroon E.G., Sachs D., Cunha F.Q., Bukin E., Atrasheuskaya A., Ignatyev G., and Teixeira M.M. Essential role of platelet-activating factor receptor in the pathogenesis of Dengue virus infection. Proc. Natl. Acad. Sci. U.S.A. 106 33 (2009) 14138-14143
126. Sriburi R., Keelapang P., Duangchinda T., Pruksakorn S., Maneekarn N., Malasit P., and Sittisombut N. Construction of infectious dengue 2 virus cDNA clones using high copy number plasmid. J. Virol. Methods 92 1 (2001) 71-82
127. Srikiatkhachorn A., Ajariyakhajorn C., Endy T.P., Kalayanarooj S., Libraty D.H., Green S., Ennis F.A., and Rothman A.L. Virus-induced decline in soluble vascular endothelial growth receptor 2 is associated with plasma leakage in dengue hemorrhagic fever. J. Virol. 81 4 (2007) 1592-1600
128. Stadler K., Allison S.L., Schalich J., and Heinz F.X. Proteolytic activation of tick-borne encephalitis virus by furin. J. Virol. 71 11 (1997) 8475-8481
129. Talavera D., Castillo A.M., Dominguez M.C., Gutierrez A.E., and Meza I. IL8 release, tight junction and cytoskeleton dynamic reorganization conducive to permeability increase are induced by dengue virus infection of microvascular endothelial monolayers. J. Gen. Virol. 85 Pt 7 (2004) 1801-1813
130. Tan B.H., Fu J., Sugrue R.J., Yap E.H., Chan Y.C., and Tan Y.H. Recombinant dengue type 1 virus NS5 protein expressed in Escherichia coli exhibits RNA-dependent RNA polymerase activity. Virology 216 2 (1996) 317-325
131. Tassaneetrithep B., Burgess T.H., Granelli-Piperno A., Trumpfheller C., Finke J., Sun W., Eller M.A., Pattanapanyasat K., Sarasombath S., Birx D.L., Steinman R.M., Schlesinger S., and Marovich M.A. DC-SIGN (CD209) mediates dengue virus infection of human dendritic cells. J. Exp. Med. 197 7 (2003) 823-829
132. Tatarowicz W.A., Lurain N.S., and Thompson K.D. In situ ELISA for the evaluation of antiviral compounds effective against human cytomegalovirus. J. Virol. Methods 35 2 (1991) 207-215
133. Thepparit C., and Smith D.R. Serotype-specific entry of dengue virus into liver cells: identification of the 37-kilodalton/67-kilodalton high-affinity laminin receptor as a dengue virus serotype 1 receptor. J. Virol. 78 22 (2004) 12647-12656
134. Valle R.P., and Falgout B. Mutagenesis of the NS3 protease of dengue virus type 2. J. Virol. 72 1 (1998) 624-632
135. van der Schaar H.M., Rust M.J., Chen C., van der Ende-Metselaar H., Wilschut J., Zhuang X., and Smit J.M. Dissecting the cell entry pathway of dengue virus by single-particle tracking in living cells. PLoS Pathog. 4 12 (2008) e1000244
136. von Moeller H., Basquin C., and Conti E. The mRNA export protein DBP5 binds RNA and the cytoplasmic nucleoporin NUP214 in a mutually exclusive manner. Nat. Struct. Mol. Biol. 16 3 (2009) 247-254
137. Wang Q.Y., Patel S.J., Vangrevelinghe E., Xu H.Y., Rao R., Jaber D., Schul W., Gu F., Heudi O., Ma N.L., Poh M.K., Phong W.Y., Keller T.H., Jacoby E., and Vasudevan S.G. A small-molecule dengue virus entry inhibitor. Antimicrob. Agents Chemother. 53 5 (2009) 1823-1831
138. Wengler G. Terminal sequences of the genome and replicative-form RNA of the flavivirus West Nile virus: absence of poly(A) and possible role in RNA replication. Virology 113 2 (1981) 544-555
139. Wengler G., and Wengler G. The carboxy-terminal part of the NS 3 protein of the West Nile flavivirus can be isolated as a soluble protein after proteolytic cleavage and represents an RNA-stimulated NTPase. Virology 184 2 (1991) 707-715
140. Wengler G., and Wengler G. The NS3 nonstructural protein of flaviviruses contains an RNA triphosphatase activity. Virology 197 (1993) 265-273
141. Whitby K., Pierson T., Geiss B., Lane K., Engle M., Zhou Y., Doms R., and Diamond M. Castanospermine, a potent inhibitor of dengue virus infection in vitro and in vivo. J. Virol. 79 14 (2005) 8698-8706
142. Wu J., Bera A., Kuhn R., and Smith J. Structure of the Flavivirus helicase: implications for catalytic activity, protein interactions, and proteolytic processing. J. Virol. 79 16 (2005) 10268-10277
143. Wu J.Z., Yao N., Walker M., and Hong Z. Recent advances in discovery and development of promising therapeutics against hepatitis C virus NS5B RNA-dependent RNA polymerase. Mini Rev. Med. Chem. 5 12 (2005) 1103-1112
144. Wu S.-F., Lee C.-J., Liao C.-L., Dwek R., Zitzmann N., and Lin Y.-L. Antiviral effects of an iminosugar derivative on flavivirus infections. J. Virol. 76 8 (2002) 3596-3604
145. Xu T., Sampath A., Chao A., Wen D., Nanao M., Chene P., Vasudevan S., and Lescar J. Structure of the Dengue virus helicase/nucleoside triphosphatase catalytic domain at a resolution of 2.4 A. J. Virol. 79 16 (2005) 10278-10288
146. Yamashita T., Unno H., Mori Y., Tani H., Moriishi K., Takamizawa A., Agoh M., Tsukihara T., and Matsuura Y. Crystal structure of the catalytic domain of Japanese encephalitis virus NS3 helicase/nucleoside triphosphatase at a resolution of 1.8 A. Virology 373 2 (2008) 426-436
147. Yap T., Xu T., Chen Y., Malet H., Egloff M., Canard B., Vasudevan S., and Lescar J. Crystal structure of the dengue virus RNA-dependent RNA polymerase catalytic domain at 1.85-angstrom resolution. J. Virol. 81 9 (2007) 4753-4765
148. Yedavalli V.S., Neuveut C., Chi Y.H., Kleiman L., and Jeang K.T. Requirement of DDX3 DEAD box RNA helicase for HIV-1 Rev-RRE export function. Cell 119 3 (2004) 381-392
149. Yedavalli V.S., Zhang N., Cai H., Zhang P., Starost M.F., Hosmane R.S., and Jeang K.T. Ring expanded nucleoside analogues inhibit RNA helicase and intracellular human immunodeficiency virus type 1 replication. J. Med. Chem. 51 16 (2008) 5043-5051
150. Yin Z., Chen Y.-L., Schul W., Wang Q.-Y., Gu F., Duraiswamy J., Reddy K.R., Niyomrattanakit P., Lakshminarayana S.B., Goh A., Xu H.Y., Liu W., Liu B., Lim J.Y.H., Ng C.Y., Qing M., Lim C.C., Yip A., Wang G., Chan W.L., Tan H.P., Lin K., Zhang B., Zou G., Bernard K.A., Garrett C., Beltz B., Dong M.M.W., He H., Han X., Pichota A., Dartois V., Keller T.H., and Shi P.-Y. An adenosine nucleoside inhibitor of dengue virus. Proc. Natl. Acad. Sci. U.S.A. 106 48 (2009) 20435-20439
151. Yusof R., Clum S., Wetzel M., Murthy H.M., and Padmanabhan R. Purified NS2B/NS3 serine protease of dengue virus type 2 exhibits cofactor NS2B dependence for cleavage of substrates with dibasic amino acids in vitro. J. Biol. Chem. 275 14 (2000) 9963-9969
152. Zhang S., Vogt M.R., Oliphant T., Engle M., Bovshik E.I., Diamond M.S., and Beasley D.W. Development of resistance to passive therapy with a potently neutralizing humanized monoclonal antibody against West Nile virus. J. Infect. Dis. 200 2 (2009) 202-205
153. Zhou Y., Ray D., Zhao Y., Dong H., Ren S., Li Z., Guo Y., Bernard K., Shi P.Y., and Li H. Structure and function of flavivirus NS5 methyltransferase. J. Virol. 81 8 (2007) 3891-3903
154. Zuo Z., Liew O.W., Chen G., Chong P.C., Lee S.H., Chen K., Jiang H., Puah C.M., and Zhu W. Mechanism of NS2B-mediated activation of NS3pro in dengue virus: molecular dynamics simulations and bioassays. J. Virol. 83 2 (2009) 1060-1070